SOMERSET, NJ – December 16, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”),a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares (“ADSs”), each representing two ordinary shares, at […]

SOMERSET, NJ – December 14, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it intends to offer and sell $300.0 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, […]

  Updated CARTITUDE-1 data presented at ASH 2021 demonstrate a 98 percent overall response rate and 83 percent stringent complete response rate after nearly two years of follow-up CARTITUDE-1 study data also reported 2-year progression-free survival and overall survival rates were 61 and 74 percent, respectively New results from CARTITUDE-2 study of cilta-cel in earlier […]

SOMERSET, N.J.— (BUSINESS WIRE)—December 7, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that it will host a hybrid event featuring key opinion leaders (KOLs) in multiple myeloma on Monday, December 13 at 8pm ET. The meeting will detail new and updated data from […]

Submission based on data from pivotal CARTITUDE-1 trial SOMERSET, N.J., — (BUSINESS WIRE) — December 06, 2021 – Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene […]